Personalising pancreas cancer treatment: When tissue is the issue

Katrin M. Sjoquist, Venessa T. Chin, Lorraine A. Chantrill, Chelsie O'Connor, Chris Hemmings, David K. Chang, Angela Chou, Marina Pajic, Amber L. Johns, Adnan M. Nagrial, Andrew V. Biankin, Desmond Yip*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX (fuorouracil, leucovorin, irinotecan and oxaliplatin) and nab-paclitaxelgemcitabine have demonstrated some improved outcomes. Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course. This has allowed identification of potentially actionable mutations that may be targeted by new biological agents. The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition. This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice.

Original languageEnglish
Pages (from-to)7849-7863
Number of pages15
JournalWorld Journal of Gastroenterology
Issue number24
Publication statusPublished - 2014
Externally publishedYes


Dive into the research topics of 'Personalising pancreas cancer treatment: When tissue is the issue'. Together they form a unique fingerprint.

Cite this